Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01052506 · ClinicalTrials.gov registry record · Phase 1
BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT01052506 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 72 participants.
The verdict
NCT01052506, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the safety and tolerability of single dose of BIIB033 administered to healthy adult volunteers.
Interventions
- DRUG Placebo
- DRUG BIIB033
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2010-01 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01052506
The ClinicalTrials.gov registry entry for NCT01052506 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01052506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01052506 about?
NCT01052506 is a clinical study titled "BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects". The primary objective of the study is to evaluate the safety and tolerability of single dose of BIIB033 administered to healthy adult volunteers.
What is the current status of trial NCT01052506?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2010-01. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01052506?
The interventions under investigation include: Placebo (DRUG), BIIB033 (DRUG).
Who is sponsoring clinical trial NCT01052506?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.